Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

D. James, Nicholas; R. Sydes, Matthew; W. Clarke, Noel; D. Mason, Malcolm; P. Dearnaley, David; Spears, Melissa; Ritchie, A.W.S.; Parker, Christopher; M. Russell, John; Attard, Gerhardt; S. de Bono, Johann; Cross, William; J. Jones, Robert; N. Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, S.; Birtle, Alison; Brock, Susannah; Cathomas, Richard; Chakraborti, Prabir; Chowdhury, Simon; Cook, Audrey; Elliott, Tony; Gale, Joanna; Gibbs, Stephanie; D. Graham, John; Hetherington, John; Hughes, Robert; Laing, Robert; McKinna, Fiona; B. McLaren, Duncan; M. O’Sullivan, Joe; Parikh, Omi; Peedell, C.; Protheroe, Andrew; Robinson, Angus; Srihari, Narayanan; Srinivasan, Rajaguru; Staffurth, John; Sundar, Santhanam; Tolan, Shaun; Tsang, David; Wagstaff, John; Parmar, Mahesh

doi:10.1016/s0140-6736(15)01037-5

Public

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Published in The Lancet • Dec 21, 2015

Authors:

Nicholas D. James

Matthew R. Sydes

Noel W. Clarke

Abstract

BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are ...

Subject

Medicine

Docetaxel

Zoledronic acid

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!